• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibito

  2026-04-29

  Pladevall-Morera et al. identify that high-grade glioma cells lacking ATRX are especially susceptible to multi-targeted RTK and PDGFR inhibitors. This work highlights ATRX status as a potential biomarker for therapy stratification and suggests new avenues for targeted combination treatments in aggressive gliomas.

• Targeting BCL-XL and MCL-1 Sensitizes Glioblastoma to Apopto

  2026-04-28

  Koessinger et al. demonstrate that glioblastoma (GBM) cells display increased expression of anti-apoptotic proteins BCL-XL and MCL-1, rendering them highly sensitive to BH3-mimetic inhibitors. Sequential inhibition of these proteins induces robust tumor apoptosis in preclinical models, supporting new targeted therapeutic strategies for GBM.

• Vacuolin-1: Unraveling Lysosomal Exocytosis in Disease Pathw

  2026-04-28

  Explore how Vacuolin-1, a potent lysosomal exocytosis inhibitor, enables advanced investigation of lysosome-mediated disease mechanisms and membrane repair. This article uniquely bridges mechanistic insights with assay design, setting it apart from conventional guides.

• Pseudo-UTP Revolutionizes mRNA Synthesis with Pseudouridine

  2026-04-27

  Pseudo-UTP enables robust mRNA synthesis by seamlessly incorporating pseudouridine, boosting RNA stability and minimizing immunogenicity. This breakthrough empowers next-generation mRNA vaccine and gene therapy development, with APExBIO’s high-purity reagent setting a new benchmark for consistency.

• Tunable Human Intestinal Organoids: Balancing Renewal and Di

  2026-04-27

  This study establishes a human intestinal organoid system that enables a controlled equilibrium between stem cell self-renewal and differentiation, overcoming previous limitations of cellular homogeneity and limited proliferative capacity. By employing combinations of small molecule pathway modulators, the researchers achieve a scalable and diverse organoid model with implications for high-throughput applications and disease modeling.

• CTCF Maintains Centromere Structure and Mitotic Fidelity

  2026-04-26

  This study demonstrates that the chromatin looping factor CTCF is essential for centromere function and accurate mitotic division in human cells. Using rapid degron-mediated depletion, the authors show CTCF loss disrupts chromosome alignment and post-mitotic nuclear shape, revealing a new facet of centromere maintenance relevant to mitosis-focused cancer research.

• Annexin V-FITC/PI Apoptosis Assay Kit: Translational Insight

  2026-04-25

  Explore the Annexin V-FITC/PI Apoptosis Assay Kit for advanced early apoptosis detection. This article uniquely bridges apoptosis assay technology with translational insights from renal disease models, offering evidence-based guidance for complex research applications.

• Losmapimod (GW856553X): Dual-Action Innovation in p38 MAPK R

  2026-04-24

  This thought-leadership article explores how Losmapimod (GW856553X) is redefining the paradigm of p38 MAPK inhibition for translational researchers. Integrating new mechanistic findings on dual-action kinase inhibition and dephosphorylation, the article provides a strategic roadmap for leveraging Losmapimod in inflammation, vascular, and hypertension research. By synthesizing state-of-the-art structural insights, comparative analyses, and practical workflow recommendations, this piece elevates the discussion beyond standard product pages and positions Losmapimod from APExBIO as a next-generation tool for translational success.

• Super-Enhancer RNA Drives NPC Metastasis via NPM1/c-Myc/NDRG

  2026-04-24

  This study reveals how carcinogen-induced super-enhancer RNA (seRNA-NPCm) promotes metastasis in nasopharyngeal carcinoma (NPC) by regulating the NPM1/c-Myc/NDRG1 pathway. The findings clarify a novel epigenetic mechanism underlying NPC progression and provide mechanistic insights for future therapeutic strategies.

• HyperScript First-Strand cDNA Synthesis Kit: Resolving Low C

  2026-04-23

  Discover how the HyperScript First-Strand cDNA Synthesis Kit enables precise reverse transcription of low-abundance and structurally complex RNA, advancing research in inflammatory disease models. This article reveals unique assay design strategies and lessons from molecular ARDS studies.

• AKTIP as a Diagnostic Biomarker in Fibrolamellar Carcinoma

  2026-04-23

  This study identifies AKTIP as a robust diagnostic and prognostic biomarker for fibrolamellar carcinoma (FLC) using integrated WGCNA and machine learning. The findings advance molecular diagnosis of FLC and propose four compounds as potential targeted therapies, with practical implications for gene expression analysis workflows.

• Proteinase K: Broad-Spectrum Serine Protease for DNA Purity

  2026-04-22

  Proteinase K from APExBIO empowers researchers with robust protein digestion and contaminant removal, preserving DNA integrity even in challenging sample matrices. Its recombinant production in Pichia pastoris ensures high activity, inhibitor resistance, and reproducibility, setting the gold standard for genomic DNA isolation and advanced molecular biology workflows.

• AI-Driven Discovery of Senolytics: Innovation in Targeting S

  2026-04-22

  The reference study demonstrates how machine learning can efficiently identify novel senolytic compounds by leveraging heterogeneous published data. This approach not only reduces drug screening costs hundreds of fold, but also expands the arsenal of agents for selectively eliminating senescent cells—key in cancer and age-related disease research.

• AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosid

  2026-04-21

  This article addresses critical workflow challenges in cell viability and metabolic assays, highlighting how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), SKU A8184, enables reproducible AMPK activation, robust inflammation inhibition, and streamlined laboratory protocols. Evidence-based Q&A scenarios guide researchers in optimizing assay design and vendor selection for reliable, high-impact metabolic disease research.

• Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) in Vascular

  2026-04-21

  Angiotensin II (SKU A1042) is an octapeptide tool for controlled induction of hypertension, vascular smooth muscle cell hypertrophy, and cardiovascular remodeling in preclinical models. Researchers should use it for mechanism studies in vascular biology, not for diagnostic or therapeutic purposes. Strict adherence to recommended handling, storage, and dosing protocols is required for reproducibility.

407 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page